کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
1931143 | 1050542 | 2011 | 6 صفحه PDF | دانلود رایگان |

Protein-bound polysaccharide K (PSK) is a clinical immunotherapeutic agent that exhibits various biological activities, including anti-tumor and anti-microbial effects. In the present study, we report on the anti-prion activity of PSK. It inhibited the formation of protease-resistant abnormal prion protein in prion-infected cells without any apparent alterations in either the normal prion protein turnover or the autophagic function in the cells. Its anti-prion activity was predominantly composed of the high molecular weight component(s) of the protein portion of PSK. A single subcutaneous dose of PSK slightly but significantly prolonged the survival time of peritoneally prion-infected mice, but PSK-treated mice produced neutralizing antibodies against the anti-prion activity of PSK. These findings suggest that PSK is a new anti-prion substance that may be useful in elucidating the mechanism of prion replication, although the structure of the anti-prion component(s) of PSK requires further evaluation.
Research highlights
► Our findings provide the first evidence of protein-bound polysaccharide K (PSK) as a new type of anti-prion compound.
► K PSK has anti-prion activity in vitro and in vivo.
► High molecular weight protein component(s) of PSK mainly cause anti-prion activity.
► PSK may be useful in elucidating the mechanism of prion replication.
Journal: Biochemical and Biophysical Research Communications - Volume 405, Issue 2, 11 February 2011, Pages 285–290